ArticleMolecular and cellular biochemistry2026
Exploring the beneficial effects of curcumin-based hydrogel beads in rats with rheumatoid arthritis induced by Freund's complete adjuvant.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Natural Bioactive Compounds in Rheumatoid Arthritis: Experimental Evidence from Adjuvant Arthritis Model Supporting Combination Strategies with Methotrexate.International journal of molecular sciences · 2026Review
- Hydrogels as Local Structural-Protective Platforms in Rheumatoid Arthritis: An Evidence-Graded Review Across the Synovium-Cartilage-Bone Axis.Gels (Basel, Switzerland) · 2026Review
- Epitranscriptomic regulation by m6A in immunity and autoimmune disorders: emerging mechanisms and clinical perspectives.Frontiers in immunology · 2026Review
- Epigenetic modifier m⁶A methylation: insights into the pathogenesis and therapeutic potential of autoimmune diseases.Journal of translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The aim of this study was to examine the potential antioxidant activity of curcumin in therapeutic and preventive condition and its potential role as adjuvant to conventional drug methotrexate in treatment of rheumatoid arthritis (RA). The study included 104 female Wistar albino rats, 6 weeks old, body weight of 200-250 g, which were divided into 8 groups (n=13 in each group): 1. CTRL: negative control, 2. CUR: positive control 1 (curcumin 200 mg/kg three times a week for 4 weeks per os), 3. MTX: positive control 2 (methotrexate 0,75 mg/kg i.p. two times a week for 4 weeks), 4. RA: positive control 3 (induced RA), 5. RA+pCUR: rats with induced RA + preventive administration of curcumin (curcumin 200 mg/kg three times a week for 4 weeks per os before the induction of RA), 6. RA+tCUR: rats with induced RA + curcumin therapy, 7. RA+MTX+pCUR; rats with induced RA + preventive administration of curcumin + methotrexate 0.75 mg/kg i.p. twice weekly for 4 weeks, 8. RA+MTX+tCUR: rats with induced RA + therapeutic administration of curcumin + methotrexate 0.75 mg/kg i.p. twice weekly for 4 weeks. Potential therapeutic effect of curcumin (200 mg/kg three times a week for 4 weeks orally) and RA induction were initiated on the same day; for preventive protocol, curcumin was administered 4 weeks before the start of RA induction at a dose of 200 mg/kg orally three times a week. Rheumatoid arthritis was triggered by administering 0.1 ml of Complete Freund's Adjuvant (CFA) subcutaneously at the base of the rat tail. Rats were sacrificed 28 days after immunization. During the experimental period, we collected data for arthritis score, radiography testing, and blood sample collecting for specific biochemical analysis for prooxidative and antioxidative parameters (superoxide anion radical, hydrogen peroxide, nitric oxide, index of lipid peroxidation, superoxide dismutase, catalase, and reduced glutathione). Our experimental study confirmed that the therapeutic administration of curcumin reduced disease activity and significantly increased the activities of antioxidative enzymes and reduced prooxidants. Also, preventive administration, especially in combination with methotrexate, offers superior protection by limiting the onset and development of oxidative stress. These findings support the claim that curcumin as turmeric can effectively inhibit inflammatory reactions and reduces symptoms through changing the redox status. Future large randomized controlled trials on the effects of turmeric substance are needed.
Indexed as
Identifiers
40911277What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.